Macular edema is the most common cause of visual loss among patients with uveitis. Although there are multiple approaches to the treatment of uveitic macular edema, no comparative trials of these treatments have been performed. The goal of this proposal is to address two critical issues in the treatment of uveitic macular edema 1) the optimal initial treatment for uveitic macular edema; and 2) the optimal treatment of persistent macular edema (i.e. macular edema that has not resolved after initial treatment). Regional corticosteroid injections are the mainstay of treatment for uveitic macular edema. However, there are different routes and formulations, which never have been compared in a trial, and the lack of definitive trials has led to considerable variability in clinical practice. For persistent macular edema, repeat injections of corticosteroids typically are administered. However, pilot studies of intravitreal methotrexate and of intravitreal ranibizumab (Lucentis) have suggested efficacy, possibly with fewer ocular side effects then comparative trials have been performed of these approaches. The existing MUST Research Group uveitic macular edema.
The specific aims of the trials are: 1) to compare the relative effectiveness of periocular traimcinolone acetonide, intravitreal triamoinoione acetonide (Triescence), and the intravitreal dexamethasone implant (Ozurdex) for the treatment of uveitic macular edema; and 2) to compare the relative effectiveness of intravitreal ranizizumab (Lucentis), intravitreal methotrexate, and theintravitreal dexamethasone implant (Ozuradex) for the treatment of uveitic macular edema that persists after intravitreal triamoinolone injections. The results of these trials will guide clinicians regarding the best approaches for issues based upon both its breadth of expertise and proven track record, demonstrated by the successful completion of the MUST trial and by the ongoing MUST Follow-up Study of participants in the MUST Trial.
Uveitis is associated with high rates of visual loss, typically caused by structural complications, of which uveitic macular edema is among the most common. Furthermore, macular edema is the most frequent cause of visual loss among patients with uveitis. The two proposed comparative effectiveness trials will provide an evidence base to guide clinicians in the management of uveitic macular edema.
| Multicenter Uveitis Steroid Treatment Trial Research Group; Writing Committee:; Thorne, Jennifer E et al. (2018) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology : |
